Stock Events

Oncocyte 

$3.21
23
+$0.09+2.88% Friday 20:00

Statistics

Day High
3.25
Day Low
3.1
52W High
4.64
52W Low
2.08
Volume
27,567
Avg. Volume
75,285
Mkt Cap
42.9M
P/E Ratio
-0.65
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-2.12
-1.44
-0.75
-0.07
Expected EPS
-0.76
Actual EPS
-2.12

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

4.42$Average Price Target
The highest estimate is $5.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
In-Vitro Diagnostic Substance Manufacturing
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
CEO
Employees
43
Country
US
ISIN
US68235C1071
WKN
000A2ACBH

Listings